

available at [www.sciencedirect.com](http://www.sciencedirect.com)journal homepage: [www.elsevier.com/locate/biochempharm](http://www.elsevier.com/locate/biochempharm)

# The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines

Tomoko Nishimaki-Mogami<sup>a,\*</sup>, Norimasa Tamehiro<sup>a</sup>, Yoji Sato<sup>a</sup>, Kei-ichiro Okuhira<sup>a</sup>, Kimie Sai<sup>a</sup>, Hiroyuki Kagechika<sup>b</sup>, Koichi Shudo<sup>d</sup>, Sumiko Abe-Dohmae<sup>c</sup>, Shinji Yokoyama<sup>c</sup>, Yasuo Ohno<sup>a</sup>, Kazuhide Inoue<sup>a,1</sup>, Jun-ichi Sawada<sup>a</sup>

<sup>a</sup> National Institute of Health Sciences, Tokyo, Japan

<sup>b</sup> School of Biomedical Science, Tokyo Medical and Dental University, Tokyo, Japan

<sup>c</sup> Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

<sup>d</sup> Itsu Research Institute, Tokyo, Japan

## ARTICLE INFO

### Article history:

Received 24 June 2008

Accepted 4 August 2008

### Keywords:

Retinoid X receptor modulator  
Peroxisome proliferator-activated receptor  $\gamma$   
Liver X receptor  
ABCA1  
HDL

## ABSTRACT

Release of cellular cholesterol by ATP-binding cassette transporter (ABC)A1 and apolipoproteins is a major source of plasma high-density lipoprotein (HDL). Expression of ABC transporter A1 (ABCA1) is directly stimulated by liver X receptor (LXR)/retinoid X receptor (RXR) activation. We evaluated the abilities of two RXR agonists, PA024 and HX630, to increase ABCA1 expression. In differentiated THP-1 cells, the two agonists efficiently enhanced ABCA1 mRNA expression and apoA-I-dependent cellular cholesterol release. However, in RAW264 cells and undifferentiated THP-1 cells, PA024 was highly effective while HX630 was inactive in increasing ABCA1 mRNA. In parallel, the two agonists had different abilities to activate ABCA1 promoter in an LXR-responsive-element (LXRE)-dependent manner and to directly stimulate LXR $\alpha$ /RXR transactivation. The ability of HX630 to enhance ABCA1 expression was correlated closely with the cellular PPAR $\gamma$  mRNA level. Moreover, HX630 was able to activate PPAR $\gamma$ /RXR. Transfection of PPAR $\gamma$  in RAW264 cells induced HX630-mediated activation of LXRE-dependent transcription and ABCA1 promoter, suggesting the ability of HX630 to activate PPAR $\gamma$ -LXR-ABCA1 pathway. We conclude that RXR agonist PA024 and HX630 have different abilities to activate LXR/RXR, and that the cell-type-dependent effect of HX630 on ABCA1 expression and HDL generation is closely associated with this defect.

© 2008 Elsevier Inc. All rights reserved.

## 1. Introduction

ABC transporter A1 (ABCA1) mediates and rate-limits biogenesis of high-density lipoprotein (HDL) from helical apolipo-

protein acceptors, such as apoA-I, and cellular cholesterol and phospholipids [1]. Mutations in the ABCA1 gene cause Tangier disease and other genetic HDL deficiencies [2–4]. Conversely, overexpression of ABCA1 in mice resulted in a mild elevation

\* Corresponding author at: Division of Biosignaling, National Institute of Health Sciences, Kamiyoga 1-18-1, Setagaya-ku, Tokyo 158-8501, Japan. Tel.: +81 3 3700 9478; fax: +81 3 3707 6950.

E-mail address: [mogami@nihs.go.jp](mailto:mogami@nihs.go.jp) (T. Nishimaki-Mogami).

<sup>1</sup> Present address: Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

0006-2952/\$ – see front matter © 2008 Elsevier Inc. All rights reserved.

doi:10.1016/j.bcp.2008.08.005

of HDL cholesterol [5,6] and has been shown to protect animals from atherosclerosis [7,8]. Plasma HDL levels are inversely related to the risk of atherosclerotic cardiovascular disease [9], presumably because HDL functions to remove excess cholesterol from peripheral tissues and transport it to the liver for conversion to bile acids [10]. Accordingly, therapies that increase ABCA1 expression are a promising strategy for preventing and treating atherogenesis.

Cellular expression of ABCA1 is highly regulated. Loading cholesterol into macrophages and fibroblasts resulted in enhanced transcription of the ABCA1 gene by the reaction mediated by the oxysterol-activated liver X receptor (LXR) [11–14]. ABCA1 expression can also be increased by PPAR $\alpha$  or PPAR $\gamma$  activators [15].

Retinoid X receptor (RXR) is a member of the nuclear receptor superfamily and forms heterodimers with a number of other receptors. RXR heterodimers, such as the peroxisome proliferator-activated receptor (PPAR)/RXR, LXR/RXR and the farnesoid X receptor (FXR)/RXR, can be activated by agonists for both RXR and the partner receptors and are classified as permissive heterodimers [16–18]. The thyroid hormone receptor/RXR or vitamin D receptor/RXR are not activated by RXR agonists and termed as non-permissive heterodimers [16–18]. A natural RXR agonist, 9-*cis*-retinoic acid, and synthetic RXR-selective ligands (rexinoids) have been shown to increase ABCA1 expression in macrophages [12,19,20].

In the present study, we evaluated the ability of two RXR agonists, PA024 and HX630, to induce ABCA1 expression in macrophage cell lines. Both PA024 and HX630 have been developed as RXR-selective agonists and are inactive alone in the HL-60 differentiation assay but strongly enhance the activity of low concentration of RAR-selective agonist AM80 [21]. However, their effects on the other RXR heterodimers are unknown. We found that PA024 potently induces ABCA1 expression in all cell models examined. However, HX630 failed to induce ABCA1 expression in RAW264 cells and undifferentiated THP-1 cells, and this defect was closely associated with the lack of ability to activate LXR/RXR. Instead, HX630 was able to activate PPAR $\gamma$ /RXR and induce ABCA1 expression in differentiated THP-1 cells. Our data also suggest the ability of HX630 to stimulate the PPAR $\gamma$ -LXR-ABCA1 pathway.

## 2. Materials and methods

### 2.1. Materials

22(R)-hydroxycholesterol and phorbol 12-myristate 13-acetate (PMA) was obtained from Sigma; troglitazone from BIOMOL Research Laboratories Inc. (Plymouth Meeting, PA, USA) HX630, PA024, and Am80 were prepared as described previously [21–23].

### 2.2. Cell culture and real time quantitative RT-PCRs

RAW264 cells were obtained from the Riken Gene Bank (Tsukuba, Japan) and maintained in Dulbecco's modified Eagle's medium (DMEM)/F-12 (1:1) containing 10% fetal calf serum. Cells were incubated for 24 h in serum-free medium containing 0.1% BSA in the presence or absence of 22(R)-hydroxycholes-


terol (2  $\mu$ g/ml) and RXR agonists. THP-1 cells were maintained in RPMI 1640 medium containing 10% fetal calf serum. Cells were treated with RXR agonists in serum-free medium containing 0.2% BSA. Differentiation of THP-1 cells into macrophages was induced by treatment of the cells with 100 nM PMA for 48 h. RXR agonists were added to the medium during the last 24 h. Cells were harvested and total RNA was extracted using an RNeasy Mini Kit (Qiagen). The RNA samples were treated with DNase according to the manufacturer's protocol (Qiagen). Relative expression levels of mRNA were determined using a TaqMan one-step RT-PCR Master Mix Reagent Kit and an ABI Prism 7700 sequence detection system (Applied Biosystems). Primer/probe sequences used were as follows: human PPAR $\gamma$  forward primer, 5'-AGGCGAGGGCGATCTTG-3', reverse primer, 5'-CCCATCAT-TAAGGAATTCATGTCAT-3', probe, 5'-FAM-CAGGAAAGACAA-CAGACAAATCACCATTTCGT-TAMRA3'. The primer/probe sequences for mouse ABCA1 [24], human ABCA1, human ABCG1, and human LXR $\alpha$  [25] were the same as described previously. Expression data were normalized to 18S rRNA levels, and presented as the fold difference of treated cells against untreated cells.

### 2.3. Plasmid constructs

Plasmids for a LXRE-driven luciferase reporter and a PPAR response element (PPRE)-driven luciferase reporter (pPPRE-tk-Luc) and were constructed by inserting the cDNAs containing two copies of LXREa and LXREb from the sterol response element binding protein-1c promoter and two copies of PPRE from acyl-CoA oxidase, respectively, upstream from the thymidine kinase (tk) promoter. cDNAs encoding full-length human RXR $\alpha$ , LXR $\alpha$ , LXR $\beta$ , or PPAR $\gamma$  were PCR-cloned and inserted into mammalian expression vector pcDNA3.1 (Invitrogen). A mouse peripheral-type ABCA1 promoter (–1238/+57 of exon 1)-luciferase vector (pABCA1-Luc) has been described previously [24]. A mouse ABCA1 promoter construct containing mutation in LXRE (pABCA1:mutLXRE-Luc) was prepared as described previously [26].

### 2.4. Transient transfections and reporter gene assays

RAW264 cells were transfected with 1.0  $\mu$ g of pABCA1-Luc or pABCA1:mutLXRE-Luc and 0.1  $\mu$ g of Renilla luciferase vector (phRL-TK) (Promega) with SuperFect (Qiagen) in 24-well plates. For LXR activation studies, 1  $\mu$ g of pLXRE-tk-Luc, 50 ng each of pcDNA3.1-LXR and pcDNA3.1-RXR $\alpha$ , and 0.7  $\mu$ g of pSV- $\beta$ -galactosidase control vector (Promega) were used. For the assay of PPAR $\gamma$  activation, cells were transfected with 1.3  $\mu$ g of pPPRE-tk-Luc and 0.1  $\mu$ g of Renilla luciferase vector (phRL-TK) (Promega) in the presence or absence of 50 ng each of pcDNA3.1-LXR and pcDNA3.1-RXR $\alpha$ . An empty pcDNA3.1 expression vector was used to maintain equal amounts of DNA for each transfection. Three hours after transfection, cells were exposed to RXR agonists in the medium containing 10% FCS for 24 h. Undifferentiated THP-1 cells were electroporatically transfected with 0.4  $\mu$ g of pABCA1-Luc or empty vector and 0.1  $\mu$ g of phRL-TK using the Nucleofector transfection system (Amaxa Inc., Gaithersburg, MD) according to the manufacturer's protocol. Four hours after transfection, cells were exposed to RXR agonists in the medium containing 0.2%



**Fig. 1 – Effects of PA024 and HX630 on ABCA1 mRNA expression and cholesterol efflux in RAW264 cells, PMA-differentiated, and undifferentiated THP-1 cells. (A)** RAW264 cells were treated for 24 h with PA024 or HX630 in the absence or presence of 22(R)-hydroxycholesterol (22RHC, 2  $\mu$ g/ml). ABCA1 mRNA levels were measured with quantitative real-time RT-PCR analysis, standardized against 18S rRNA levels, and expressed as fold induction relative to the vehicle-treated cells (V, taken as 1). **(B)** PMA-differentiated or undifferentiated THP-1 cells were treated for 24 h with 100 nM PA024 or HX630. ABCA1 mRNA/18S rRNA levels were expressed as fold induction relative to the vehicle-treated undifferentiated cells. **(C)** PA024 and HX630 enhance apoA-I mediated cholesterol efflux and

FCS for 24 h. Luciferase and  $\beta$ -galactosidase activities were determined in cell lysates. Firefly luciferase activity was normalized to either that of Renilla luciferase or  $\beta$ -galactosidase for each well.

## 2.5. Coactivator association assay using fluorescence polarization

The assay was performed as described previously [27]. Briefly, TAMRA-labeled peptide (100 nM, with amino acid sequence ILRKLLQE) was incubated for 1 h with purified GST-fused human PPAR $\gamma$  LBD (1.5  $\mu$ M) and ligands in 100  $\mu$ l of buffer (10 mM Hepes, 150 mM NaCl, 2 mM MgCl $_2$ , 5 mM DTT at pH 7.9) in a black polypropylene 96-well plate on a shaker. Ligand-dependent recruitment of the coactivator peptide was measured as increases in fluorescence polarization with a Fusion $\alpha$ -FP (PerkinElmer Life Science).

## 2.6. Measurement of lipid efflux to apolipoprotein A-I (apoA-I)

The differentiated or undifferentiated THP-1 cells were incubated in the presence or absence of 10  $\mu$ g/ml of apoA-I in RPMI 1640 containing 0.2% BSA for 24 h. Lipid was extracted from the medium and the cells with chloroform/methanol (2:1, v/v) and hexane/isopropanol (3:2, v/v), respectively, and cholesterol and choline-phospholipid were determined by enzymatic methods specific for each lipid [28].

## 2.7. Statistical analysis

Data were analyzed by ANOVA followed by the Student-Newman-Keuls method. Statistical significance was established at the  $P < 0.05$  level.

# 3. Results

## 3.1. RXR agonist PA024 and HX630 show different abilities to induce ABCA1 expression

We tested the ability of RXR agonist PA024 and HX630 to induce ABCA1 expression in murine macrophage-like cell line, RAW264. Treatment of RAW264 cells with PA024 markedly induced ABCA1 mRNA expression, which peaked at 100 nM, whereas HX630 up to 1  $\mu$ M had no effect (Fig. 1A left). Expression of ABCA1 can be stimulated by oxysterol-activated

decrease the cellular cholesterol level in differentiated THP-1 cells. PMA-differentiated or undifferentiated THP-1 cells were treated for 24 h with 100 nM PA024 or HX630 in the presence or absence of apoA-I (15  $\mu$ g/ml). ApoA-I-dependent release of cholesterol into the medium and cellular total cholesterol ( $2.69 \pm 0.77$   $\mu$ g/mg protein and  $15.31 \pm 0.39$   $\mu$ g/mg protein, respectively, in control cells) were expressed as fold induction relative to the vehicle-treated undifferentiated cells. The values represent the average  $\pm$  S.D. from three experiments. Significantly different from vehicle-treated cells (\*).

LXR [11,13,14]. The addition of 22(R)-hydroxycholesterol to the medium increased ABCA1 expression and strongly enhanced the effect of PA024 (Fig. 1A right). This combination had a greater than additive effect, whereas HX630 again had no effect.


The effect of two RXR agonists on ABCA1 expression was also studied in a human monocytic leukemia cell line, THP-1 (Fig. 1B). PA024 (100 nM) increased the ABCA1 mRNA level both in PMA-differentiated and undifferentiated cells (by 4- and 7-fold, respectively). In contrast, HX630 (100 nM) did not affect the ABCA1 mRNA level in undifferentiated cells. However, the same concentration of HX630 did raise the ABCA1 mRNA level in PMA-differentiated cells by 1.6-fold.

ABCA1 has been shown to play a critical role in the assembly of HDL from apoA-I and cellular cholesterol and phospholipids. We examined the effect of the two RXR agonists on apoA-I-mediated cholesterol release (HDL production) in THP-1 cells (Fig. 1C). HX630 and PA024 at 100 nM increased the amount of cholesterol released into the medium in the presence of apoA-I (by 2- and 3.4-fold, respectively) in differentiated cells, and this increase was accompanied by a decrease in the cellular total cholesterol level. In contrast, the same concentration of HX630 had no effect in undifferentiated cells.

### 3.2. PA024 but not HX630 activates LXR/RXR and ABCA1 promoter

To determine whether the different abilities of the two RXR agonists in ABCA1 mRNA induction were resulted from different abilities in ABCA1 gene transcription, we examined their effects on ABCA1 promoter activity. An ABCA1 promoter (−1238/+57 of exon 1)-luciferase construct was transfected into RAW264 cells. As shown in Fig. 2A, PA024 markedly increased the ABCA1 promoter transcription, and the increase caused by PA024 was lost when a mutation was introduced into LXRE in the promoter. In contrast, HX630 up to 1  $\mu$ M had no effect on the promoter activity. Similarly, when the ABCA1 promoter was transfected into undifferentiated THP-1 cells, PA024 augmented the promoter activity in an LXRE-dependent manner, but HX630 had no effect (Fig. 2B). These findings indicate that PA024-induced activation of ABCA1 promoter was mediated by LXRE. We intended to examine the promoter activity in PMA-differentiated THP-1 cells. However, transfection of the plasmid into the differentiated THP-1 cells was unsuccessful. In addition, cells harboring transfected DNA did not undergo differentiation with PMA.


The possibility that PA024 but not HX630 activates LXR/RXR was tested using a reporter assay. Transfection of the LXRE-driven luciferase-reporter vector alone into RAW264 cells yielded substantial luciferase activity, indicating transcriptional activation by endogenous receptor(s), and this endogenous LXRs-mediated activity was increased by PA024, but not HX630 (Fig. 3 left). Co-transfection of LXR $\alpha$  and RXR $\alpha$  expression vectors enhanced the effect of PA024, whereas HX630 again had no effect (Fig. 3 middle). Expressions of LXR $\beta$  and RXR $\alpha$  augmented luciferase transcription in the vehicle-treated control (Fig. 3 right). However, the response elicited by PA024 was small and similar to that in cells without LXR/RXR plasmids (Fig. 3 left). HX630 again had no effect.



**Fig. 2 – PA024 but not HX630 augments ABCA1 promoter activity in RAW264 cells (A) and undifferentiated THP-1 cells (B).** Cells were transfected with a pABCA1-Luc (closed symbols) or pABCA1:mutLXRE-Luc (open symbols) reporter plasmid together with a pRL-TK internal control as described in Section 2.4, and treated with indicated concentrations (for A) or 100 nM (for B) of PA024 and HX630. Luciferase activity in the cell extract was normalized using Renilla luciferase activity and expressed as fold induction relative to vehicle-treated cells (indicated as V). The data represent the average  $\pm$  S.D. of three experiments. Significantly different from vehicle-treated cells (\*) or LXRE-mutated promoter (†).


### 3.3. HX630 and PA024 activate PPAR $\gamma$ /RXR

The ability of HX630 and PA024 to activate PPAR $\gamma$ /RXR was tested in RAW264 cells transfected with a PPRE-driven luciferase-reporter vector (Fig. 4A). When PPAR $\gamma$ /RXR was transfected into the cells, the two agonists markedly increased luciferase activity. RXR-homodimer has been shown to activate transcription of the DR-1 element [29]. Upon transfection of



**Fig. 3 – PA024 but not HX630 augments LXR $\alpha$ /RXR transactivation.** RAW264 cells were transfected with LXREx4-tk-Luc reporter plasmid together with a  $\beta$ -gal internal control in the absence (A) or presence of expression plasmids for human LXR $\alpha$  and RXR $\alpha$  (B) or LXR $\beta$  and RXR $\alpha$  (C). The cells were treated with the indicated concentrations of PA024 or HX630. Luciferase activity in the cell extract was normalized using  $\beta$ -gal and expressed as fold induction relative to vehicle-treated cells (indicated as V). The data represent the average  $\pm$  S.D. of three incubations.





**Fig. 4 – PA024 and HX630 stimulate PPAR $\gamma$ /RXR transactivation.** (A) RAW264 cells were transfected with a pPRE-tk-Luc reporter plasmid together with a pRL-TK internal control in the presence or absence of expression plasmids for human PPAR $\gamma$  and RXR $\alpha$ . The cells were treated with 100 nM PA024 or HX630 for 24 h before analysis. (B) Dose-response of RXR agonists for activation of a reporter gene by PPAR $\gamma$ /RXR. Cells were transfected with a pPRE-tk-Luc reporter plasmid in the absence (open symbols) or presence (closed symbols) of the PPAR $\gamma$  expression plasmid and treated with drugs for 24 h. Luciferase activity stimulated by PPAR $\gamma$  and endogenous RXR in the cell extract was determined, normalized, and expressed as fold induction relative to vehicle-treated cells without exogenous receptor expression. The values represent the average  $\pm$  S.D. of three incubations. (C) RXR agonists do not affect binding of troglitazone to PPAR $\gamma$ . A fluorescent-tagged SRC-1 peptide (0.1  $\mu$ M) was incubated with 1.5  $\mu$ M PPAR $\gamma$  ligand binding domain in the presence of various concentrations of PA024 and HX630 in the presence or absence of 10  $\mu$ M troglitazone (Tz). Ligand-induced association of coactivator peptide with the receptor was monitored by increases in millipolarization fluorescence units (mP).


RXR $\alpha$  alone, the two agonists increased luciferase activity, indicating substantial activation of RXR $\alpha$  homodimer. However, when PPAR $\gamma$  alone was co-transfected, both agonists greatly enhanced transcription, suggesting that they have abilities to activate PPAR $\gamma$ /RXR heterodimer made from exogenous PPAR $\gamma$  and endogenous RXR. In this reporter assay system using exogenous PPAR $\gamma$  and endogenous RXR, HX630 activated PPAR $\gamma$ /RXR-dependent transcription more potently than PA024 at concentrations higher than 100 nM (Fig. 4B). To exclude the possibility that the HX630 and PA024 bind to PPAR $\gamma$  as a ligand, coactivator-association assay was performed. As shown in Fig. 4C, neither HX630 nor PA024 induced an interaction between fluorescence-labeled coactivator peptide

and the PPAR $\gamma$  ligand binding domain *in vitro*, while the PPAR $\gamma$  agonist troglitazone strongly induced association. Furthermore, these RXR agonists did not affect the PPAR $\gamma$ -coactivator interaction elicited by 10  $\mu$ M troglitazone. These findings indicate that the two RXR agonists were able to activate PPAR $\gamma$ /RXR.


#### 3.4. Possible stimulation of PPAR $\gamma$ -LXR-ABCA1 pathway by HX630

LXR $\alpha$  gene is known to be a direct target of PPAR $\gamma$ /RXR, and stimulation of PPAR $\gamma$  has been shown to increase LXR-target gene expression by increasing LXR $\alpha$  expression [30]. We therefore examined the ability of HX630 to enhance LXR-target gene transcription by activating PPAR $\gamma$ /RXR. LXRE-driven luciferase assay was performed in RAW264 cells with or without co-transfection of PPAR $\gamma$ . As shown in Fig. 5A, HX630 augmented luciferase transcription in the presence but not in the absence of PPAR $\gamma$ . This effect was enhanced by increasing the amount of the PPAR $\gamma$  expression plasmid and the combination of HX630 and the LXR agonist 22(R)-hydroxycholesterol had an additive effect. The activity of ABCA1 promoter was also increased by HX630 when PPAR $\gamma$  was co-transfected (Fig. 5B).

The level of PPAR $\gamma$  mRNA was very low in undifferentiated THP-1 cells (not treated with PMA) but up-regulated during differentiation with PMA (Fig. 6). The levels of PPAR $\gamma$ -target gene CD36 and LXR $\alpha$  mRNA were unaffected by HX630 (100 nM) in undifferentiated cells but increased in PMA-differentiated cells (by 1.4- and 1.6-fold, respectively). In parallel with these changes, LXR $\alpha$ -target ABCG1 expression was unaffected by HX630 in undifferentiated THP-1 cells but increased in differentiated cells (by 3.9-fold). PA024 (100 nM) effectively raised ABCG1 and LXR $\alpha$  levels in undifferentiated



**Fig. 5 – HX630 activates LXRE-driven luciferase (A) or ABCA1 promoter (B) gene transcription upon co-expression of PPAR $\gamma$ .** RAW264 cells were transfected with an LXRE4-tk-Luc or a pABCA1-Luc reporter plasmid and a pRL-TK internal control in the presence of 0–0.2  $\mu$ g of PPAR $\gamma$  plasmid and treated for 24 h with 100 nM HX630 in the presence or absence of 0.5  $\mu$ g/ml 22(R)-hydroxycholesterol (22RHC). Luciferase activity in the cell extract was determined and normalized. The values represent the average  $\pm$  S.D. of three experiments. Significantly different from respective control (\*) or vehicle-treated cells (†).



**Fig. 6 – PA024 and HX630 increase LXR- and PPAR $\gamma$ -target gene expressions in PMA-differentiated THP-1 cells.** PMA-differentiated or undifferentiated THP-1 cells were treated for 24 h with 100 nM PA024 or HX630. The expressions of ABCG1, PPAR $\gamma$ , and LXR $\alpha$  mRNA were measured as described in the legend to Fig. 1B. The values represent the average  $\pm$  S.D. relative to the PMA-treated control cells (taken as 1) from three experiments. \* Significantly different from vehicle-treated cells.

cells, and the effect was drastically increased in PMA-differentiated cells.

#### 4. Discussion

In the present study, we found that RXR agonist PA024 efficiently enhanced ABCA1 mRNA expression in all cell lines tested and strongly promoted apoA-I-mediated cholesterol release (HDL generation) from PMA-differentiated THP-1 cells (Fig. 1B and C). However, HX630 was unable to raise the ABCA1 mRNA level in RAW264 cells (Fig. 1A) and undifferentiated THP-1 cells (Fig. 1B), but was active in differentiated THP-1 cells (Fig. 1B).

The different abilities of the two agonists to induce ABCA1 mRNA expression in RAW264 cells and undifferentiated THP-1 cells were paralleled with their different abilities to activate ABCA1 promoter (Fig. 2). PA024 increased the ABCA1 promoter activity in an LXRE-dependent manner, suggesting that the effect of PA024 was primarily mediated by LXR/RXR activation. Indeed, PA024 strongly stimulated LXR $\alpha$ /RXR-dependent transcription in a cellular transactivation assay (Fig. 3). In contrast, HX630 failed to stimulate the ABCA1 promoter activity. Because HX630 had no capability to directly activate LXR/RXR, suggesting that the failure of ABCA1 induction by HX630 is attributable to this defect.

However, HX630 was able to increase ABCA1 mRNA expression and promote apoA-I-mediated cholesterol release (HDL generation) in PMA-differentiated THP-1 cells (Fig. 1B and C). HX630 was able to induce another LXR-target gene ABCG1 mRNA expression in differentiated cells but not in undifferentiated cells (Fig. 6). These findings suggest that HX630 might increase LXR-target gene transcription in differentiated THP-1 cells.

The LXR $\alpha$  gene is known to be a direct target of PPAR $\gamma$ , and stimulation of PPAR $\gamma$  by agonists has been shown to increase ABCA1 expression by raising LXR $\alpha$  level [30]. We showed that both HX630 and PA024 were able to activate PPAR $\gamma$ /RXR in a cellular transactivation assay (Fig. 4). Furthermore, if PPAR $\gamma$ -expression plasmid was co-transfected into RAW264 cells, HX630 was able to stimulate an LXRE-dependent reporter gene transcription and the ABCA1 promoter activity, as well (Fig. 5). These findings suggest the ability of HX630 to stimulate the PPAR $\gamma$ -LXR-ABCA1 pathway. The level of PPAR $\gamma$  mRNA was greatly induced by differentiation of THP-1 cells with PMA (Fig. 6). In addition, the differentiation augmented HX630-mediated expression of LXR-target ABCA1 and ABCG1 and PPAR $\gamma$ -target LXR $\alpha$  and CD36. Both endogenous PPAR $\gamma$  activity (Fig. 4A and B) and HX630-induced ABCA1 expression (Fig. 1A) were undetectable in RAW264 cells. These findings indicate a close correlation between the ability of HX630 to enhance LXR-target gene expression and the cellular PPAR $\gamma$  mRNA level. The activation of PPAR $\gamma$ /RXR by HX630 primary may elevate LXR $\alpha$  and thereby enhances ABCA1 expression in PMA-differentiated THP-1 cells. Possibility remains that HX630 stimulates LXR/RXR in this cell model. However, we were unable to investigate this possibility due to very low efficiency in DNA transfection in PMA-differentiated cells. Another possibility is that activation of RXR heterodimer(s) other than PPAR $\gamma$ /RXR may also be responsible for the HX630-mediated ABCA1 expression in this cell line. A study has shown that RAR activators increase ABCA1 expression in mouse peripheral macrophages, and that RAR/RXR stimulated the ABCA1 promoter activity via the same DR4 element as LXR/RXR [31]. However, when PMA-differentiated THP-1 cells were treated with RAR agonist AM80 [21], the ABCA1 mRNA level was unchanged (data not shown), suggesting that the RAR/RXR-mediated promoter activation may not make a large contribution to ABCA1 expression in this cell line.

Inductions of ABCA1 and HDL generation by PA024 and HX630 were accompanied by a decrease in the cellular cholesterol level (Fig. 1C). In particular, our findings show the effectiveness of direct activation of LXR/RXR by PA024 (Fig. 3). Although LXR/RXR is known to be permissive in terms

of RXR agonist activation [16,17], HX630 was unable to activate LXR/RXR (Fig. 3). Administration of RXR agonists to mice leads to increases in HDL cholesterol levels [20]. RXR modulators are promising therapeutic strategies [32]. However, increases in serum triglyceride due to RXR agonists are postulated to occur via activation of LXR/RXR, leading to enhanced lipogenesis in response to induction of hepatic SREBP-1c expression [33]. Heterodimer-selective RXR agonists without the ability to directly activate LXR/RXR, may be a promising target for the development of drugs without adverse effects. Synthetic RXR agonists that retain the ability to activate PPAR $\gamma$ /RXR, but have less effect on LXR/RXR and RAR/RXR, have been reported, and pharmacological advantages of these heterodimer-selective RXR agonists as anti-diabetes agents have been demonstrated [34]. The molecular basis of such heterodimer selectivity has not fully been clarified. The mechanism underlying HX630 heterodimer selectivity awaits further investigation.

## Acknowledgments

This work was supported in part by a grant from the Japan Health Sciences Foundation, a grant (MF-16) from the Organization for Pharmaceutical Safety and Research, and Grant-in-Aid for Scientific Research 20590116 from Japan Society for the Promotion of Science.

## REFERENCES

- [1] Yokoyama S. Assembly of high-density lipoprotein. *Arterioscler Thromb Vasc Biol* 2006;26:20–7.
- [2] Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. *Nat Genet* 1999;22:347–51.
- [3] Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. *Nat Genet* 1999;22:336–45.
- [4] Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat Genet* 1999;22:352–5.
- [5] Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and apoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. *J Biol Chem* 2001;276:33969–7.
- [6] Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, Shamburek RD, et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. *J Clin Invest* 2001;108:303–9.
- [7] Joyce CW, Amar MJ, Lambert G, Vaisman BL, Paigen B, Najib-Fruchart J, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. *Proc Natl Acad Sci USA* 2002;99:407–12.
- [8] Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, et al. Increased ABCA1 activity protects against atherosclerosis. *J Clin Invest* 2002;110:35–42.
- [9] Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. *Am J Med* 1977;62:707–14.
- [10] Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. *J Lipid Res* 1995;36:211–28.
- [11] Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. *J Biol Chem* 2000;275:28240–5.
- [12] Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. *Biochem Biophys Res Commun* 1999;257:29–33.
- [13] Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and apoA-I-mediated cholesterol efflux are regulated by LXR. *Biochem Biophys Res Commun* 2000;274:794–802.
- [14] Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR  $\alpha$ . *Proc Natl Acad Sci USA* 2000;97:12097–102.
- [15] Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR- $\alpha$  and PPAR- $\gamma$  activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nat Med* 2001;7:53–8.
- [16] Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. *Science* 2001;294:1866–70.
- [17] Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. *Cell* 1995;83:841–50.
- [18] Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. *Nature* 1997;386:407–10.
- [19] Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. *Proc Natl Acad Sci USA* 2001;98:2610–5.
- [20] Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. *Science* 2000;289:1524–9.
- [21] Kagechika H, Shudo K. Synthetic retinoids: recent developments concerning structure and clinical utility. *J Med Chem* 2005;48:5875–83.
- [22] Ohta K, Kawachi E, Inoue N, Fukasawa H, Hashimoto Y, Itai A, et al. Retinoidal pyrimidinecarboxylic acids. Unexpected diaza-substituent effects in retinobenzoic acids. *Chem Pharm Bull (Tokyo)* 2000;48:1504–13.
- [23] Umemiya H, Fukasawa H, Ebisawa M, Eyrolles L, Kawachi E, Eisenmann G, et al. Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers. *J Med Chem* 1997;40:4222–34.
- [24] Suzuki S, Nishimaki-Mogami T, Tamehiro N, Inoue K, Arakawa R, Abe-Dohmae S, et al. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism. *Arterioscler Thromb Vasc Biol* 2004;24:519–25.
- [25] Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. *J Biol Chem* 2001;276:38378–87.
- [26] Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, et al. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. *J Biol Chem* 2007;282:21090–9.

- [27] Nishimaki-Mogami T, Une M, Fujino T, Sato Y, Tamehiro N, Kawahara Y, et al. Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor. *J Lipid Res* 2004;45:1538–45.
- [28] Abe-Dohmae S, Suzuki S, Wada Y, Aburatani H, Vance DE, Yokoyama S. Characterization of apolipoprotein-mediated HDL generation induced by cAMP in a murine macrophage cell line. *Biochemistry* 2000;39:11092–9.
- [29] Umemiya H, Kagechika H, Fukasawa H, Kawachi E, Ebisawa M, Hashimoto Y, et al. Action mechanism of retinoid-synergistic dibenzodiazepines. *Biochem Biophys Res Commun* 1997;233:121–5.
- [30] Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. *Mol Cell* 2001;7:161–71.
- [31] Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, et al. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. *Mol Cell Biol* 2003;23:7756–66.
- [32] Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. *Nat Rev Drug Discov* 2007;6:793–810.
- [33] Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. *Genes Dev* 2000;14:2831–8.
- [34] Michellys PY, Ardecky RJ, Chen JH, Crombie DL, Etgen GJ, Faul MM, et al. Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes. *J Med Chem* 2003;46:2683–96.